Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

Fig. 1

Markov model included five health states: mild (FEV1 > 70%), moderate (FEV1 40–70%), severe (FEV1 < 40%), post-transplant and death and two transition states: pulmonary exacerbation and lung transplant. Transitions to improved states were not allowed for the usual care arm. In some scenarios, transitions to improved states were allowed for the treatment arm

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172